Johnson & Johnson (JNJ) CEO Talks About Turn Around In Their Consumer Segment Business

Drug major Johnson & Johnson (NYSE:JNJ) Chairman of the Board, Chief Executive Officer Alex Gorsky in a wide ranging interview with Carol Massar of Bloomberg TV on its “Bloomberg West” program shared his firm’s road map to grow the business over the next few years via strategic acquisitions and his plans to streamline operations by going in for divestures to help increase share holder value.

Johnson & Johnson (JNJ)

The $291.17 billion market capped Johnson & Johnson (NYSE:JNJ) has a complex business which is divided into three major segments. Of these segments, the interviewer kick-started her interview by quizzing Mr Alex Gorsky about the status of it’s under pressure Consumer segment business, which had come under public scrutiny for recall of products.

 Mr Gorsky went on to underline that Johnson & Johnson (NYSE:JNJ) “is very committed to the consumer segment” and the segment “plays an important role in the company’s business”. He then went on to express his happiness at the steps taken by the company to “remediate the over the counter products in North America” by stating that, “I am very impressed with the progress that the division has made over the past few years.”

The Chief executive then went on to spell out how Johnson & Johnson (NYSE:JNJ) operates in a different manner today in comparison to the 2008 and 2009 time frame, when the drug major was hit by a spate of product recalls. The changes listed out include the complete revamp of the “supply chain and quality measurement systems.” The changes centered on more “centralized operations of the quality department, standardization of the manufacturing process and increased checks and balances across the organization”.

Mr Gorsky then went on to acknowledge that, “We are seeing results of those hard work and efforts now. We saw an impressive 9 percent increase in the OTC numbers in North America this quarter.”

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!